Codiak BioSciences

66 articles with Codiak BioSciences

• 

  Flagship’s Afeyan Outlines Biotech’s Top 4 Trends

  1/14/2022

  Today, Noubar Afeyan, founder of Flagship Pioneering, published the platform development company’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.

• Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

  1/6/2022

  Codiak BioSciences, Inc. announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.

• Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine

  12/2/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced new preclinical data from its exoVACC™ exosome-based vaccine platform.

• Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference

  12/1/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced that Douglas E. Williams, Ph.D., President and CEO, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.

• Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022

  11/30/2021

  Codiak BioSciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for exoASO-STAT6.

• Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts

  11/16/2021

  Codiak BioSciences, Inc. today announced positive initial data for exoSTING, a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors.

• New Preclinical Data at SITC 2021 Show Broad Potential Utility of Codiak’s Engineered Exosomes

  11/12/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that new preclinical data from programs using its engEx™ Platform will be presented this week at the 36th Annual Meeting of the Society for Immunotherapy of Cancer.

• Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress

  11/4/2021

  Codiak BioSciences, Inc. today reported third quarter 2021 financial results and recent operational progress.

• Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration

  11/2/2021

  Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline

• Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  10/1/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters featuring preclinical data from its engEx™ Platform programs will be presented during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021).

• Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

  8/18/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Lini Pandite, MBChB, MBA to its board of directors.

• 

  Codiak BioSciences Un-Strands Assets with Extracellular Vesicles

  8/16/2021

  Codiak has two engineered exosome programs in Phase I, each showing different types of engineering possibilities to deliver targeted payloads that pharmaceutical companies haven’t managed to push all the way through the clinic.

• Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress

  8/5/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2021 financial results and operational progress.

• Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

  7/7/2021

  Codiak BioSciences, Inc. today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in two virtual panel discussions and virtual 1x1 meetings at the William Blair Biotech Focus Conference 2021.

• Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

  7/6/2021

  Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that Benny Sorensen, M.D., Ph.D. resigned from his position as a Senior Vice President of Strategic Projects to become CEO of a privately held biotech company, Hemab Therapeutics, focused on rare bleeding and thrombosis disorders.

• Codiak BioSciences Expands Executive Leadership

  6/15/2021

  Codiak BioSciences, Inc. today announced the promotion of Sriram Sathyanarayanan, Ph.D.

• Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

  6/2/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:

• Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

  5/20/2021

  Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.

• 

  BioSpace Movers & Shakers, May 14

  5/14/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.

• New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

  5/11/2021

  Data at ASGCT 2021 show ability to design exosomes with specific features for immune evasion, tunable vaccine development, targeted cell tropism and potent target engagement